Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Overview of attention for article published in Cancer Discovery, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 3 news outlets
twitter: 28 X users

wikipedia: 1 Wikipedia page
guideline: 2 clinical guideline sources

Readers on

mendeley: 216 Mendeley

So far, Altmetric has seen 49 X posts from 28 X users, with an upper bound of 144,072 followers.

6/9 Venetoclax plus navitoclax RR ALL including T-cell. CR ~ 50%, myelosuppression was important safety finding. Venetoclax combinations are being explored for management of RR ALL. https://t.co/StrhwLEuXT

RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 45 additional X posts.